Patheon was founded in 1974 and is headquartered in Durham, US
Patheon Office Locations
Patheon has an office in Durham
Durham, US (HQ)
300 4815 Emperor Blvd
Patheon Financials and Metrics
Patheon Financials
Patheon's revenue was reported to be $1 b in FY, 2013
USD
Revenue (FY, 2013) | 1 b |
Gross profit (FY, 2013) | 249.1 m |
Gross profit margin (FY, 2013), % | 24% |
Net income (FY, 2013) | (35.9 m) |
EBIT (FY, 2013) | 33.9 m |
Market capitalization (01-Sep-2017) | 5.1 b |
Cash (31-Oct-2013) | 61.6 m |
EV | 5.7 b |
Patheon's current market capitalization is $5.1 b.
| USD | FY, 2013 |
|---|---|
Revenue | 1 b |
Cost of goods sold | 774 m |
Gross profit | 249.1 m |
Gross profit Margin, % | 24% |
| USD | FY, 2013 |
|---|---|
Cash | 61.6 m |
Accounts Receivable | 191.3 m |
Inventories | 137.8 m |
Current Assets | 415.7 m |
| USD | FY, 2013 |
|---|---|
Depreciation and Amortization | 48.4 m |
Cash From Operating Activities | 13 m |
Cash From Financing Activities | 306.9 m |
Interest Paid | 42.1 m |
| Y, 2013 | |
|---|---|
EV/EBIT | 167 x |
EV/CFO | 435.4 x |
Debt/Equity | 4.8 x |
Debt/Assets | 0.6 x |
Financial Leverage | 8.5 x |
Patheon Market Value History
Patheon Median Salaries
Source: 16 public H-1B filings from Patheon
Market Position of Patheon
Traffic Overview of Patheon
Patheon Online and Social Media Presence
Patheon News and Updates
September 26, 2017
Pharmaceutical Solid Dosage Contract Manufacturing Market to witness steady increase by 2024
The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 13, 2017
Pharmaceutical Solid Dosage Contract Manufacturing Market: Industry Latest Trends & Global Outlook 2016-2024
The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday
August 14, 2017
Vicarius Pharma lands $21.8 mln
Switzerland-based Vicarius Pharma AG, which provides U.S.-based biopharmaceutical companies a "novel approach" to commercializing assets in European markets, has raised $21.8 million in funding. James Mullen, CEO of Patheon and former CEO of Biogen, was the lead investor.
June 08, 2017
BRIEF-Patheon reports Q2 adjusted earnings of $0.20/shr from continuing operations
* Q2 adjusted earnings per share $0.20 from continuing
operations
May 16, 2017
Patheon, built on a series of acquisitions, is snapped up by Thermo Fisher in $7.2B deal
Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion.
May 15, 2017
Thermo Fisher to buy drug ingredients maker Patheon for $5.2 billion
(Reuters) - Thermo Fisher Scientific Inc said on Monday it would buy Dutch drug ingredients maker Patheon NV , as it looks to become a one-stop shop for contract drug development and manufacturing.